anticancer/hypoxia

BACKGROUND The vasculature associated with fast proliferating solid tumors is abnormal, which limits efficient oxygen supply and renders the tumor tissue hypoxic. The presence of hypoxic areas in solid cancers has been correlated with resistance to chemotherapy and radiation treatment. Intratumoral

FIELD OF THE INVENTION The present invention relates to metabolically activated sulfonyl hydrazine prodrugs (SHPs) exhibiting anti-tumor activity in mammals. Methods of treating neoplasia, especially including cancer are additional aspects of the present invention. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention provides methods and compositions for treating cancer with hypoxia activated prodrugs administered alone and in combination with anticancer drugs that are not hypoxically activated and/or in combination with radiation therapy. The invention relates to the

BACKGROUND Field of the Invention Maintenance of physiological oxygen concentrations is a highly dynamic process vital to many aspects of cell biology. Lack of oxygen (hypoxia) is a frequently encountered situation in solid tumors and is associated with increased radiotherapy and chemotherapy

This application is the U.S. National Phase of International Application PCT/NZ2006/000064, filed 31 Mar. 2006, which designated the U.S. PCT/)NZ2006/000064 claims priority to New Zealand Application No. 539152, filed 31 Mar. 2005, and New Zealand Application No. 542556, filed 22 Sep. 2005. The

FIELD OF THE INVENTION This application relates to the field of immune response, specifically to the use of bioactive agents (compounds) that interfere with HIF-1.alpha. expression and/or transcriptional activities and HIF-1.alpha. inhibitors and therefore modulate (i.e. decrease or increase)

TECHNICAL FIELD The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) gene products in a hypoxic cell. More particularly, the presently disclosed subject matter provides methods and

This application is the U.S. National Phase of International Application PCT/NZ2003/000225, filed Oct. 8, 2003, which designated the U.S. PCT/NZ2003/000225 claims priority to New Zealand Application No. NZ 521851 filed Oct. 8, 2002. The entire content of these applications are incorporated herein by

CROSS-REFERENCES TO RELATED APPLICATION This patent application is a 371 of PCT/KR2011/007710, filed on Oct. 17, 2011, which claims the benefit of Korean Patent Application No. 10-2010-0102661, filed on Oct. 20, 2010, the contents of each of which are incorporated herein by reference. BACKGROUND OF

FIELD OF THE INVENTION The methods described herein provides methods, compounds, and compositions useful in the treatment of cancer. BACKGROUND Cancer generally refers to one of a group of more than 100 diseases caused by the uncontrolled growth and spread of abnormal cells that can take the form of

FIELD OF THE INVENTION The methods described herein provides methods, compounds, and compositions useful in the treatment of cancer. BACKGROUND Cancer generally refers to one of a group of more than 100 diseases caused by the uncontrolled growth and spread of abnormal cells that can take the form of

The present disclosure relates to heterocyclic compounds, compositions, and methods to inhibit HIF pathway activity, more specifically to methods for treating diseases mediated by HIF pathway activity. The heterodimeric HIF transcription factor is composed of a stable HIF1.beta. (aka ARNT) and an

The present disclosure relates to heterocyclic compounds, compositions, and methods to inhibit HIF pathway activity, more specifically to methods for treating diseases mediated by HIF pathway activity. The heterodimeric HIF transcription factor is composed of a stable HIF1.beta. (aka ARNT) and an

CROSS REFERENCE TO RELATED APPLICATION This application is a 35 U.S.C. 371 National Phase of PCT Application No. PCT/EP2014/078876 filed Dec. 19, 2014 which claims priority to Danish Patent Application No. PA201370806 filed Dec. 20, 2013. The disclosure of these prior applications are hereby

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention generally relates to agents for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and non-toxic, and methods for their use. 2.